Please login to the form below

Not currently logged in
Email:
Password:

Lanthio Pharma bolsters management team

Dr Axel Mescheder appointed CMO of MorphoSys subsidiary 

Lanthio Pharma Dr Axel MeschederDutch biopharma firm Lanthio Pharma has appointed Dr Axel Mescheder as the new chief medical officer of its Lanthipeptide subsidiary MorphoSys.

Dr Mescheder brings over 20 years of research and development experience to the role, and moves from German contract research organisation Medpace, where he served as vice president of European medical and regulatory affairs.

Prior to this, he held the role of chief medical and development officer at both Medigene and TopoTarget, and served as a medical director at MorphoSys.

He has also held a number of research and development management positions at Pfizer's Centeon, Genetics Institute/Wyeth-Ayerst Research, and Roche.

Dr Heinz Schwer, chief executive officer of Lanthio Pharma, said: “We are very pleased to welcome Axel Mescheder at Lanthio Pharma where he will take a key role in the company's management.

“We got to know him as an excellent clinical physician and experience research and development manager and we are sure that he will further strengthen and complement our management portfolio.

“Axel's main focus will be the development of Lanthio Pharma's lanthipeptide portfolio, in particular the preparation and subsequent executive of the clinical development of MOR107.”

26th September 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics